《大行报告》麦格理升上海医药(02607.HK)目标价至21.75元 评级「跑赢大市」
麦格理发表报告表示,预计上海医药(02607.HK)分销及仿制药生产仍将占今年收入及盈利分别近97%及94%,相信公司股份市盈率倍数的增长动力包括,与康希诺生物(06185.HK)於新冠疫苗方面合作,目标是在今年年底前开始生产,以及其他内部开发和许可项目等。
该行认为,上海医药下行风险有限,加上公司药物推出的时间表,预期为公司带来重新评级的机会。该行上调其2021至2023年度每股盈利预测40%/81%/80%,以反映新冠疫苗的贡献,目标价由19.27元升至21.75元,维持「跑赢大市」评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.